pyrroles has been researched along with Prostatic Neoplasms in 127 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (2.36) | 18.2507 |
| 2000's | 39 (30.71) | 29.6817 |
| 2010's | 83 (65.35) | 24.3611 |
| 2020's | 2 (1.57) | 2.80 |
| Authors | Studies |
|---|---|
| Compérat, EM; Hassler, MR; Rebhan, K; Shariat, SF; Wasinger, G | 1 |
| He, MF; He, ZH; Sun, DY; Sun, HB; Wu, JQ | 1 |
| Campbell, H; Davies, BR; De Velasco, MA; Hatanaka, Y; Kim, Y; Klein, S; Kura, Y; MacLeod, AR; Nishio, K; Sakai, K; Sugimoto, K; Uemura, H; Yoshikawa, K | 1 |
| Albert, DH; Bellin, RJ; Bigelow, L; Bui, MH; Faivre, EJ; Fidanze, S; Fossey, SL; Hasvold, LA; Hessler, P; Huang, X; Kati, WM; Lam, LT; Lin, X; Liu, D; Longenecker, K; Lu, X; Mantena, SR; McDaniel, KF; Mehta, G; Nicolette, JJ; Panchal, SC; Park, CH; Plotnik, JP; Pratt, JK; Rosenberg, SH; Sehgal, V; Shen, Y; Sheppard, GS; Sun, C; Torrent, M; Uziel, T; Wang, L; Wilcox, D; Zhang, L | 1 |
| Chen, H; Li, H; Liu, C; Qian, B; Yao, Y; Zhang, J | 1 |
| Dervan, PB; Kurmis, AA; Nickols, NG; Welch, TR; Yang, F | 1 |
| Thoma, C | 1 |
| Bergh, A; Bergström, SH; Bovinder-Ylitalo, E; Lerner, UH; Nordstrand, A; Thysell, E; Widmark, A; Wikström, P | 1 |
| Afif-Rider, S; Bezabeh, B; Breen, S; Chen, C; Dimasi, N; Dixit, R; Gunsior, M; Harper, J; Hinrichs, MJM; Howard, PW; Masterson, L; Patel, N; Rebelatto, M; Reed, M; Ryan, PC; Ryan, PM; Tiberghien, A; Vashisht, K; Yu, XQ; Zheng, B; Zhong, H | 1 |
| Pathania, S; Rawal, RK | 1 |
| Chang, L; Chen, G; Guo, Y; Hu, W; Li, G; Shah, K; Tian, H; Wang, L; Yan, Y; Yang, T; Zhang, Y | 1 |
| Chen, J; Fu, B; Li, K; Liu, T | 1 |
| Dervan, PB; Kurmis, AA | 1 |
| Du, C; Fu, S; Wan, X; Wang, H; Wang, Z; Zhou, J | 1 |
| Cai, J; Imperato-McGinley, J; Li, J; Wen, J; Weng, C; Yang, K; Yuan, H; Zhao, Y; Zhu, YS | 1 |
| Corn, PG; DePetrillo, TA; Heath, E; Kuban, D; Maier, J; Mathew, P; Meyn, R; Song, DY | 1 |
| Cox, ME; Fazli, L; Ghaffari, M; Gleave, ME; Ibuki, N; Iu, I; Kashiwagi, M; Nakanishi, O; Pandey, M; Tojo, H | 1 |
| Lamoureux, F; Zoubeidi, A | 1 |
| Dong, B; Jha, BK; Nguyen, CT; Polyakova, I; Silverman, RH | 1 |
| Broggini, M; Ceruti, R; Ganzinelli, M; Geroni, C; Sabatino, MA | 1 |
| Kopelovich, L; Li, W; McCormick, DL; Mehta, RG; Peng, X; Yuan, L | 1 |
| Chintala, M; Chintala, R; Guda, M; Komarraju, AL; Mangamoori, LN; Rentala, S | 1 |
| Cheng, X; Conney, AH; Cui, XX; Ding, N; Dipaola, RS; Du, Z; Goodin, S; Huang, MT; Liu, Y; Van Doren, J; Wang, H; Zheng, X | 1 |
| Bahl, A; Castellano, D; Chen, I; Chow Maneval, E; Daugaard, G; Gschwend, J; Houede, N; Jones, R; Laestadius, F; Lechuga, MJ; Maurina, T; Michaelson, MD; Ostler, P; Ou, YC; Oudard, S; Paolini, J; Saad, F; Sengeløv, L; Stenzl, A; Ullèn, A; Wang, SL | 1 |
| Josowicz, M; Patterson, S; Saheb, A | 1 |
| Ghalali, A; Högberg, J; Stenius, U; Wiklund, F; Zheng, H | 1 |
| Fang, X; Jin, L; Li, C; Li, R; Li, S; Sun, Z | 1 |
| Dervan, PB; Puckett, JW; Raskatov, JA | 1 |
| Chen, S; Conney, AH; Cui, XX; Dipaola, RS; Goodin, S; He, Y; Huang, H; Li, D; Liu, Y; Van Doren, J; Wang, H; Zheng, X | 1 |
| Flores-Morales, A; Hekmat, O; Hjorth-Jensen, K; Iglesias-Gato, D; Jiang, N; Ke, B; Kruse, T; Niu, Y; Olsen, JV; Wang, C; Wei, W; Yan, B | 1 |
| Ashikari, D; Fujimura, T; Fujiwara, K; Fukuda, N; Inoue, S; Ito, A; Murata, Y; Nagase, H; Obinata, D; Soma, M; Takahashi, S; Takayama, K; Urano, T; Watanabe, T; Yamaguchi, K | 1 |
| Aghai, A; Barry, ST; Boer, A; Davies, BR; de Ridder, CMA; Ellston, RP; Hoeben, S; Marques, RB; Stuurman, D; Trapman, J; van Weerden, WM | 1 |
| Dervan, PB; Raskatov, JA; Szablowski, JO | 1 |
| Dong, X; Liu, L | 1 |
| Bubendorf, L; Erne, P; Frachet, A; Frismantiene, A; Kyriakakis, E; Maslova, K; Pfaff, D; Philippova, M; Resink, TJ; Ruiz, C; Vlajnic, T | 1 |
| Bernardini, M; Brossa, A; Bussolati, B; Fiorio Pla, A; Genova, T; Gkika, D; Grolez, G; Leroy, X; Prevarskaya, N; Villers, A | 1 |
| Beraldi, E; Du, C; Fazli, L; Gleave, ME; Kumano, M; Moore, S; Sorensen, P; Zhang, F; Zoubeidi, A | 1 |
| Cagnon, VH; Hetzl, AC; Kido, LA; Montico, F | 1 |
| Bu, H; Culig, Z; Eder, IE; Egger, M; Erb, HH; Feiersinger, GE; Handle, F; Klocker, H; Luef, B; Maitland, NJ; Oh, SJ; Ploner, C; Rane, JK; Santer, FR; Schäfer, G | 1 |
| Calvo, A; Diaz, R; Manrique, I; Nguewa, PA; Redrado, M | 1 |
| Burton, EA; Chartier, S; Habets, G; Jimenez-Andrade, JM; Lin, PS; Mantyh, PW; Thompson, ML; Tsai, J; West, BL | 1 |
| Dervan, PB; Hare, AA; Hargrove, AE; Kurmis, AA; Martinez, TF; Phillips, JW; Pienta, KJ; Sud, S | 1 |
| Choi, KW; Lee, CH; Oh, HL; Ryou, C; Suh, H | 1 |
| Anand, M; Armstrong, AJ; Bratt, L; Carducci, MA; Creel, P; Davis, K; George, DJ; Halabi, S; Healy, P; Hobbs, C; Kim, S; Koontz, BF; Lee, WR; Moul, JW; Mundy, K; Nguyen, M; Reimer, B; Stein, M; Tran, PT; Wood, S | 1 |
| Choi, KW; Lee, CH; Lee, J; Rhee, H; Ryou, C; Suh, H | 1 |
| Davies, BR; De Velasco, MA; Kura, Y; Nishio, K; Uemura, H; Yoshikawa, K | 1 |
| Brekken, RA; Goel, HL; Greiner, DL; Mercurio, AM; Pursell, B; Shultz, LD; Vander Kooi, CW | 1 |
| Aebischer, B; Akboga, MK; Akdamar, G; Alcalay, RN; Álvarez-Pérez, S; Aydogdu, S; Balci, KG; Barcaro, G; Bišová, K; Blanco, JL; Brewer, SH; Caruthers, SD; Ceylan, O; Chadwick, JA; Chang, DD; Che, JM; Chen, QQ; Chen, W; Chen, Z; Chung, M; Chung, W; Colecraft, HM; Coteli, E; Dogan, H; Dong, S; Elsig, S; Fahn, S; Fang, XJ; Feng, MG; Fenlon, EE; Floyd, KT; Fokdal, L; Ford, B; Fortunelli, A; Freudenberg, R; Gan-Or, Z; García, ME; Gillham, C; Giovannelli, D; Goertz, RS; Gulati, V; Haie-Meder, C; Hao, YY; Hatano, K; Hines, KJ; Hines, SM; Hirakawa, H; Hoskin, P; Hu, JH; Huang, P; Huang, Y; Hubicka, U; Inoue, Y; Ishii, N; Janssen, PM; Jin, Z; Johnson, A; Jürgenliemk-Schultz, I; Kaineder, K; Kamei, K; Kang, U; Karatas, F; Kash, TL; Katayama, Y; Keupp, J; Kirisits, C; Kisacik, H; Kodama, K; Kotzerke, J; Kryczyk, A; Kuhness, D; Kuo, S; Lanza, GM; Le Bris, N; Levin, DE; Levy, OA; Li, B; Li, H; Li, X; Liang, GD; Liang, Y; Liao, RQ; Lin, JT; Lindegaard, JC; Liong, C; Liu, B; Liu, C; Liu, GH; Liu, L; Liu, Q; Liu, X; Lowe, J; Lowery-Gionta, EG; Ma, YH; Maden, O; Mankad, V; Marder, KS; Marshall, SA; Martínez-Nevado, E; Maucksch, U; Mazeron, R; Mazzone, CM; Mazzoni, P; Mezricky, D; Mizokami, Y; Naumann, A; Navarro, M; Netzer, FP; Neurath, MF; Nie, Q; Oliva, P; Ozeke, O; Peláez, T; Pfeifer, L; Pleil, KE; Pomp, S; Pötter, R; Puckerin, AA; Rafael-Fortney, JA; Raman, SV; Rastogi, N; Řezanka, M; Řezanka, T; Rinker, JA; Rouleau, GA; Runge, R; Sahin, MD; Sakai, A; Schmieder, AH; Schmitz, AJ; Schultz, EJ; Šegedin, B; Sementa, L; Shen, Y; Shiotsuki, I; Shirahama, M; Staley, J; Starovoytov, V; Sterrer, M; Strobel, D; Sturdza, A; Subramanyam, P; Surnev, S; Swager, SA; Taeymans, J; Tan, H; Tan, LT; Tanderup, K; Temizhan, A; Terao, T; Thiele, TE; Tran, T; Tucker, MJ; Vetriani, C; Vítová, M; Wang, JP; Wang, L; Wang, M; Wang, X; Waters, CH; Weng, SX; Wickline, SA; Wildner, D; Wodarcyk, AJ; Wolf, P; Wu, L; Wu, YL; Wunderlich, G; Xiong, L; Xu, P; Yang, GS; Yang, XN; Yang, Y; Yayla, C; Ying, SH; Zachleder, V; Zhang, XG; Zhang, XK; Zhang, Y; Zheng, JY; Zhong, WZ; Zhu, J; Zhu, YJ; Żmudzki, P | 1 |
| Argyros, O; Bach, S; Baratte, B; Christoforidis, S; Daniilides, K; Evangelidis, T; Karamani, V; Kostakis, IK; Kouvari, E; Lougiakis, N; Marakos, P; Mikros, E; Papafotika, A; Pouli, N; Ruchaud, S; Skaltsounis, AL; Tamvakopoulos, C | 1 |
| Castro, P; Coleman, I; Davies, BR; Feng, S; Ittmann, M; Nelson, PS; Shao, L; Smith, PD | 1 |
| Cui, Z; Jin, X; Jin, Y; Li, X; Peng, J | 1 |
| Hashimoto, Y; Imai, K; Miyachi, H; Tanatani, A; Wakabayashi, K | 1 |
| Cumashi, A; Iacobelli, S; Lattanzio, R; Natoli, C; Piantelli, M; Rossi, C; Tinari, N | 1 |
| Asmar, L; Berry, WR; Boehm, KA; Hutson, TE; Sonpavde, G | 1 |
| Freedland, SJ; Goldberg, KC; Hamilton, RJ; Platz, EA | 1 |
| Ezell, SJ; Murugesan, S; Nadkarni, DH; Rayburn, ER; Velu, SE; Wang, F; Wang, W; Zhang, R; Zhang, Y | 1 |
| Dror Michaelson, M; Gurski, C; Kantoff, PW; Kaufman, DS; Michaelson, SZ; Oh, WK; Olivier, K; Regan, MM; Smith, MR; Spicer, B | 1 |
| Chenoweth, DM; Dervan, PB; Dose, C; Harki, DA; Phillips, JW | 1 |
| Jeon, TI; Osborne, TF; Seo, YK; Zhu, B | 1 |
| Asmar, L; Bernold, D; Berry, WR; Boehm, KA; Fleming, MT; Galsky, MD; Hutson, TE; Periman, PO; Sonpavde, G; Weckstein, D; Zhan, F | 1 |
| Baritaki, S; Bonavida, B; Chapman, A; Palladino, M; Spandidos, DA; Yeung, K | 1 |
| Fokt, RM; Gillessen, S; Ohlschlegel, C; Schmid, HP; Templeton, A | 1 |
| Kang, DY; Kim, S; Lee, HJ; Lim, JS; Song, IC; Yun, HJ | 1 |
| Baritaki, S; Berenson, J; Bonavida, B; Palladino, M; Yeung, K | 1 |
| Dunner, K; McConkey, DJ; Zhu, K | 1 |
| Aragon-Ching, JB; Dahut, WL | 1 |
| Conney, AH; Cui, XX; Gao, Z; Huang, MT; Lin, Y; Liu, Y; Rabson, A; Reddy, B; Shih, WJ; Yang, CS; Zhao, Y; Zheng, X | 1 |
| Beyer, M; Classen, S; Debey-Pascher, S; Eggle, D; Kuhn, W; Lahn, M; Mallmann, MR; Muth, C; Pölcher, M; Rudlowski, C; Schultze, JL; Staratschek-Jox, A; Zander, T | 1 |
| Bories, E; Caillol, F; Giovannini, M; Gravis, G; Jeanniard-Malet, O; Pesenti, C | 1 |
| Geng, J; Liu, B; Liu, J; Su, L; Zhao, G | 1 |
| Campiani, G; Cloonan, SM; Lawler, M; Nathwani, SM; Stronach, M; Williams, DC; Zisterer, DM | 1 |
| Alberola, V; Casinello, J; Gasent, JM; Grande, E; Laforga, JB; Provencia, M | 1 |
| Angulo, JC | 1 |
| Handal, J; Kwok, SC; Samuel, SP | 1 |
| D'Avolio, LW; Farwell, WR; Gaziano, JM; Lawler, EV; Scranton, RE | 1 |
| Espinosa, E; González, R; Merino, M; Pinto, A | 1 |
| Chen, FH; Chiang, CS; Fu, SY; Hong, JH; Jung, SM; Lee, CC; Tsai, CS; Wang, CC; Wen, CJ | 1 |
| Antón-Aparicio, LM; Cassinello, J; Castellano, D; Esteban, E; González-Larriba, JL; Grande, E; Sepúlveda, J | 1 |
| Childress, C; Parikh, A; Rukstalis, D; Toepfer, N; Yang, W | 1 |
| Haustermans, KM; Isebaert, SF; McBride, WH; Swinnen, JV | 1 |
| Chen, I; Chow Maneval, E; George, DJ; Harmon, CS; Hutson, TE; Kozloff, M; Liu, G; Logothetis, CJ; Mathew, P; Shore, ND; Wang, SL; Wilding, G; Zurita, AJ | 1 |
| Corn, PG; Dayyani, F; Gallick, GE; Logothetis, CJ | 1 |
| Canter, DJ; Golovine, K; Kolenko, VM; Kutikov, A; Makhov, P; Simhan, J; Sirohi, M; Street, R; Uzzo, RG | 1 |
| Furuya, S; Hamamura, K; Hara, T; Hitaka, T; Ito, M; Kanzaki, N; Kusaka, M; Matsunaga, N; Miyazaki, J; Santou, T; Tasaka, A; Yamada, M; Yamamoto, S; Yamaoka, M | 1 |
| Kundra, V; Li, ZG; Navone, NM; Ravoori, MK; Starbuck, MW; Vazquez, E; Wan, X; Yang, J; Yingling, JM | 1 |
| Chresta, CC; Cosulich, S; Crafter, C; Cross, D; Davies, BR; Dudley, P; Gao, B; Greenwood, H; Ji, Q; Lane, C; Li, J; Luke, R; Maynard, J; Ogilvie, D; Page, K; Pass, M; Ricketts, SA; Watson, R; Yates, J; Yu, DH; Zhang, J | 1 |
| He, Z; Mangala, LS; Rohde, LH; Theriot, CA; Wu, H; Zhang, Y | 1 |
| Canter, DJ; Golovine, K; Kolenko, VM; Kutikov, A; Makhov, PB; Simhan, J; Teper, E; Uzzo, RG | 1 |
| Jing, C; Ning, J; Yuanjie, N | 1 |
| Bridges, K; Brooks, C; Kuban, D; Mason, K; Mathew, P; Meyn, R; Sheu, T | 1 |
| Kunawudhi, A; Mahmood, U; Michaelson, MD; Palmer, EL; Saylor, PJ; Smith, MR | 1 |
| Kelly, WK; Lin, J | 1 |
| Bergeron, P; Blackwood, E; Bowman, KK; Chen, YH; Deshmukh, G; Ding, X; Epler, J; Koehler, MF; Lau, K; Lee, L; Liu, L; Ly, C; Lyssikatos, JP; Malek, S; Nonomiya, J; Oeh, J; Ortwine, DF; Pei, Z; Sampath, D; Sideris, S; Trinh, L; Truong, T; Wu, J | 1 |
| Iljin, K; Kallioniemi, O; Ketola, K | 1 |
| Crafter, C; Davies, BR; Gleave, ME; Kumano, M; Lamoureux, F; Thomas, C; Zhang, F; Zoubeidi, A | 1 |
| Dervan, PB; Li, BC; Marinov, GK; Nickols, NG; Said, JW; Yang, F | 1 |
| Mellinghoff, IK; Sawyers, CL; Tran, C | 1 |
| Curran, WJ | 1 |
| Fidler, IJ; Karashima, T; Killion, JJ; Kim, SJ; Shepherd, DL; Uehara, H | 1 |
| Dagnaes-Hansen, F; Hynes, NE; Nexø, E; Sørensen, BS; Tørring, N | 1 |
| Abdollahi, A; Debus, J; Hahnfeldt, P; Han, X; Hlatky, L; Howlett, AR; Huber, PE; Krempien, R; Lipson, KE; Trinh, T; Weber, KJ | 1 |
| Barrios, RJ; Greenberg, NM; Huss, WJ | 1 |
| Bologna, M; Fabbro, D; Festuccia, C; Longo, M; MacKay, AR; Migliaccio, S; Recchia, I; Rucci, N; Susa, M; Teti, A | 1 |
| Bair, EL; Bowden, GT; Nagle, RB; Udayakumar, TS | 1 |
| Abdollahi, A; Bischof, M; Debus, J; Grone, HJ; Hahnfeldt, P; Han, X; Hlatky, L; Huber, PE; Klenke, F; Krix, M; Lipson, KE; Poerschke, D; Roth, A; Sckell, A; Zieher, H | 1 |
| Halmos, G; Letsch, M; Nagy, A; Schally, AV; Szepeshazi, K | 1 |
| Ikeda, D; Isshiki, K; Kawada, M; Kawamura, N; Kumagai, H; Momose, I; Someno, T; Yoshimoto, Y | 1 |
| Cao, D; Hoving, K; Karrison, T; Ryan, CW; Stadler, WM; Vogelzang, NJ; Vokes, EE; Wright, R | 1 |
| Fan, D; Fidler, IJ; He, J; Killion, JJ; Kim, SJ; Langley, RR; Tsan, R; Uehara, H; Yazici, S | 1 |
| Kwon, A; Mellinghoff, IK; Sawyers, CL; Tran, C; Vivanco, I; Wongvipat, J | 1 |
| Nagy, A; Schally, AV | 1 |
| Devlin, J; Gorelik, E; Huang, X; Krasinskas, A; Lokshin, A; Raskovalova, T; Watkins, S; Wolf, SF | 1 |
| Halmos, G; Kanashiro, CA; Nagy, A; Schally, AV; Stangelberger, A; Szepeshazi, K | 1 |
| Adamovich, E; Butler, WM; Galbreath, RW; Kurko, B; Merrick, GS; Moyad, MA; Wallner, KE | 1 |
| Adamovich, E; Allen, ZA; Butler, EG; Butler, WM; Galbreath, RW; Merrick, GS; Moyad, MA; Wallner, KE | 1 |
| Courty, J; Hatziapostolou, M; Katsoris, P; Papadimitriou, E; Polytarchou, C | 1 |
| Brackenbury, WJ; Djamgoz, MB | 1 |
| Byun, SS; Han, BK; Hong, SK; Jeong, SJ; Lee, SE | 1 |
| Etienne-Grimaldi, MC; Ferrero, JM; Fischel, JL; Formento, P; Guérin, O; Hofman, P; Lo Nigro, C; Merlano, M; Milano, G | 1 |
| Daniels, GH; Faris, JE; Moore, AF | 1 |
| Avila, GE; Conney, AH; Cui, XX; Huang, MT; Kong, AN; Lin, Y; Liu, Y; Patel, J; Paulino, R; Rabson, AB; Reddy, BS; Shih, WJ; Zheng, X | 1 |
| Chen, MH; D'Amico, AV; Kantoff, PW | 1 |
| Arencibia, JM; Halmos, G; Koppan, M; Nagy, A; Plonowski, A; Schally, AV | 1 |
| Arencibia, JM; Groot, K; Halmos, G; Koppán, M; Nagy, A; Plonowski, A; Schally, AV | 1 |
| Nagy, A; Plonowski, A; Schally, AV; Sun, B; Szepeshazi, K | 1 |
| Groot, K; Halmos, G; Nagy, A; Plonowski, A; Schally, AV; Sun, B | 1 |
| Halmos, G; Nagy, A; Plonowski, A; Schally, AV; Sun, B | 1 |
10 review(s) available for pyrroles and Prostatic Neoplasms
| Article | Year |
|---|---|
Basal cell carcinoma of the prostate: a case report responding to the FGFR inhibitor pemigatinib and literature review.
Topics: Carcinoma, Basal Cell; Humans; Lymph Node Excision; Male; Middle Aged; Morpholines; Prostate; Prostatectomy; Prostatic Neoplasms; Pyrimidines; Pyrroles; Skin Neoplasms | 2022 |
Pyrrolopyrimidines: An update on recent advancements in their medicinal attributes.
Topics: Animals; Anti-Retroviral Agents; Antineoplastic Agents; HIV Infections; Humans; Male; Molecular Structure; Prostatic Neoplasms; Protein Kinase Inhibitors; Protein Kinases; Pyrimidines; Pyrroles; Structure-Activity Relationship | 2018 |
Topics: AC133 Antigen; Acenaphthenes; Acer; Acrosome Reaction; Adult; Agaricales; Aged; Aged, 80 and over; Animals; Animals, Zoo; Anti-Bacterial Agents; Anticoagulants; Antifungal Agents; Antimanic Agents; Antioxidants; Aortic Valve; Area Under Curve; ATP Binding Cassette Transporter, Subfamily G, Member 2; Bacillus; Bacterial Toxins; Bacterial Typing Techniques; Base Composition; Beauveria; Binge Drinking; Biomarkers; Bipolar Disorder; Blood Coagulation; Blotting, Western; Brachytherapy; Calcium Channels, L-Type; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; Cell Wall; Cells, Cultured; Ceramics; Chi-Square Distribution; China; Chlorophyll; Chlorophyta; Chloroplasts; Cholesterol, HDL; Chromatography, High Pressure Liquid; Chromobacterium; Clostridium perfringens; Clozapine; Constriction, Pathologic; Coronary Artery Bypass; Corticotropin-Releasing Hormone; Cross-Sectional Studies; Cytochrome P-450 CYP2C9; Dental Porcelain; Dental Restoration Failure; Dental Stress Analysis; Designer Drugs; Diaminopimelic Acid; DNA Fingerprinting; DNA, Bacterial; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Drug Dosage Calculations; Drug Evaluation, Preclinical; Drug Resistance, Bacterial; Elasticity Imaging Techniques; Epsilonproteobacteria; Equipment Design; Ericaceae; Excitatory Amino Acid Antagonists; False Negative Reactions; Fatty Acids; Female; Food Analysis; Fresh Water; Gene Expression Regulation, Neoplastic; Glutathione; Graft Occlusion, Vascular; Heart Valve Prosthesis Implantation; Heart Ventricles; HEK293 Cells; Hemolymph; Humans; Hyaluronan Receptors; Hydrogen Peroxide; Hydrothermal Vents; Indoles; Inflammation Mediators; Inhibitory Concentration 50; Insecta; International Normalized Ratio; Isotope Labeling; Itraconazole; Kidney; Kinetics; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Lamotrigine; Lanthanoid Series Elements; Limit of Detection; Linear Models; Lipid Peroxidation; Liver; Liver Cirrhosis; Logistic Models; Lung Neoplasms; Lymph Node Excision; Lymphatic Metastasis; Male; Malondialdehyde; Mediastinum; Metronidazole; Mice; Mice, Nude; Mice, Transgenic; Microbial Sensitivity Tests; Microscopy, Fluorescence; Middle Aged; Monocytes; Monomeric GTP-Binding Proteins; Multivariate Analysis; Myocytes, Cardiac; Neoplasm Staging; Neoplastic Stem Cells; Neural Pathways; Nitrates; Nucleic Acid Hybridization; Octamer Transcription Factor-3; Odds Ratio; Oxidation-Reduction; Oxidative Stress; Peptidoglycan; Phantoms, Imaging; Pharmacogenetics; Pharmacogenomic Variants; Phenotype; Phospholipids; Photolysis; Photosynthesis; Phylogeny; Plant Extracts; Polychaeta; Polymerase Chain Reaction; Polymorphism, Single Nucleotide; Positron Emission Tomography Computed Tomography; Predictive Value of Tests; Preoperative Care; Prostatic Neoplasms; Pseudomonas aeruginosa; Pyrimidines; Pyrroles; Quorum Sensing; Radiology, Interventional; Radiopharmaceuticals; Radiotherapy Dosage; Rats; Rats, Sprague-Dawley; Receptors, Corticotropin-Releasing Hormone; Reference Values; Regression Analysis; Retrospective Studies; Reverse Transcriptase Polymerase Chain Reaction; Rhizosphere; Risk Factors; RNA, Ribosomal, 16S; ROC Curve; Rutin; Saphenous Vein; Seawater; Selenium; Semen Preservation; Sensitivity and Specificity; Septal Nuclei; Sequence Analysis, DNA; Serum Albumin; Serum Albumin, Human; Shear Strength; Sodium Pertechnetate Tc 99m; Sodium-Hydrogen Exchangers; Soil Microbiology; SOXB1 Transcription Factors; Spain; Species Specificity; Sperm Motility; Spermatozoa; Spheroids, Cellular; Spores, Fungal; Stroke; Superoxide Dismutase; Swine; Tandem Mass Spectrometry; Technetium Compounds; Technetium Tc 99m Exametazime; Technetium Tc 99m Sestamibi; Temperature; Thiosulfates; Thrombosis; Thyroid Neoplasms; Transducers; Transfection; Transplantation, Heterologous; Treatment Outcome; Triazines; Tumor Burden; Urocortins; Uterine Cervical Neoplasms; Vacuoles; Valproic Acid; Ventral Tegmental Area; Vitamin K 2; Vitamin K Epoxide Reductases; Warfarin; Water Microbiology; Young Adult | 2016 |
Prostatic metastasis of renal cell carcinoma successfully treated with sunitinib.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Male; Prostatic Neoplasms; Pyrroles; Sunitinib | 2009 |
Developments in nonsteroidal antiandrogens targeting the androgen receptor.
Topics: Androgen Receptor Antagonists; Anilides; Antineoplastic Agents; Humans; Hydantoins; Imides; Male; Nitriles; Organometallic Compounds; Oxazolone; Prostatic Neoplasms; Pyridines; Pyrroles; Receptors, Androgen; Tosyl Compounds | 2010 |
Antiangiogenic agents and endothelin antagonists in advanced castration resistant prostate cancer.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Hormonal; Atrasentan; Benzenesulfonates; Castration; Drug Resistance, Neoplasm; Endothelin Receptor Antagonists; Endothelins; Humans; Indoles; Lenalidomide; Male; Niacinamide; Phenylurea Compounds; Prostatic Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Pyrrolidines; Quinazolines; Sorafenib; Sunitinib; Thalidomide; Vascular Endothelial Growth Factor A | 2011 |
Novel therapies for metastatic castrate-resistant prostate cancer.
Topics: Androstenes; Androstenols; Angiogenesis Inhibitors; Anilides; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Atrasentan; Benzamides; Bevacizumab; Biomarkers, Tumor; Bone Remodeling; Cancer Vaccines; Clinical Trials as Topic; Clusterin; Dasatinib; Denosumab; Endothelin-1; Humans; Immunotherapy; Indoles; Ipilimumab; Male; Mice; Mice, SCID; Molecular Targeted Therapy; Nitriles; Orchiectomy; Phenylthiohydantoin; Prostate-Specific Antigen; Prostatic Neoplasms; Pyridines; Pyrimidines; Pyrroles; Pyrrolidines; RANK Ligand; Receptor Cross-Talk; Receptors, Androgen; Signal Transduction; Sunitinib; Taxoids; Thiazoles; Tissue Extracts; Treatment Failure; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2011 |
Targeting angiogenesis as a promising modality for the treatment of prostate cancer.
Topics: Angiogenesis Inhibitors; Anilides; Antibodies, Monoclonal, Humanized; Bevacizumab; Disease Progression; Drug Therapy, Combination; Humans; Indoles; Male; Prostatic Neoplasms; Pyridines; Pyrroles; Signal Transduction; Sunitinib; Thalidomide; Vascular Endothelial Growth Factor A | 2012 |
New chemotherapeutic agents: update of major chemoradiation trials in solid tumors.
Topics: Alkyl and Aryl Transferases; Angiogenesis Inhibitors; Angiostatins; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dose Fractionation, Radiation; Drugs, Investigational; Endothelial Growth Factors; Enzyme Inhibitors; Esophageal Neoplasms; Farnesyltranstransferase; Female; Head and Neck Neoplasms; Humans; Indoles; Intercellular Signaling Peptides and Proteins; Isoenzymes; Laryngeal Neoplasms; Lung Neoplasms; Lymphokines; Male; Membrane Proteins; Neoplasms; Peptide Fragments; Plasminogen; Prostaglandin-Endoperoxide Synthases; Prostatic Neoplasms; Pyrroles; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Treatment Outcome; Uterine Cervical Neoplasms; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2002 |
Targeting of cytotoxic luteinizing hormone-releasing hormone analogs to breast, ovarian, endometrial, and prostate cancers.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Doxorubicin; Endometrial Neoplasms; Epithelial Cells; Female; Gonadotropin-Releasing Hormone; Humans; Male; Ovarian Neoplasms; Prostatic Neoplasms; Pyrroles; Receptors, LHRH | 2005 |
13 trial(s) available for pyrroles and Prostatic Neoplasms
| Article | Year |
|---|---|
Sunitinib plus androgen deprivation and radiation therapy for patients with localized high-risk prostate cancer: results from a multi-institutional phase 1 study.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents; Combined Modality Therapy; Drug Interactions; Feasibility Studies; Goserelin; Humans; Indoles; Leuprolide; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Grading; Neoplasm Staging; Nitriles; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms; Pyrroles; Radiotherapy, Intensity-Modulated; Seminal Vesicles; Sunitinib; Tosyl Compounds | 2013 |
Randomized, placebo-controlled, phase III trial of sunitinib plus prednisone versus prednisone alone in progressive, metastatic, castration-resistant prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Disease Progression; Disease-Free Survival; Docetaxel; Double-Blind Method; Drug Administration Schedule; Drug Resistance, Neoplasm; Fatigue; Humans; Indoles; Kaplan-Meier Estimate; Lymphopenia; Male; Middle Aged; Neoplasm Metastasis; Orchiectomy; Prednisone; Prostatic Neoplasms; Pyrroles; Sunitinib; Taxoids; Treatment Outcome | 2014 |
A phase 2 multimodality trial of docetaxel/prednisone with sunitinib followed by salvage radiation therapy in men with PSA recurrent prostate cancer after radical prostatectomy.
Topics: Adult; Aged; Disease-Free Survival; Docetaxel; Humans; Indoles; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Prednisone; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Pyrroles; Quality of Life; Salvage Therapy; Sunitinib; Taxoids | 2016 |
Phase II trial of sunitinib for the therapy of progressive metastatic castration-refractory prostate cancer after previous docetaxel chemotherapy.
Topics: Adenocarcinoma; Androgen Antagonists; Antineoplastic Agents; Castration; Disease-Free Survival; Humans; Indoles; Male; Neoplasm Metastasis; Prostate-Specific Antigen; Prostatic Neoplasms; Pyrroles; Quality of Life; Sunitinib | 2008 |
Phase II study of sunitinib in men with advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Angiogenic Proteins; Antineoplastic Agents, Phytogenic; Docetaxel; Drug Resistance, Neoplasm; Humans; Indoles; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms; Protein Kinase Inhibitors; Pyrroles; Radiography; Sunitinib; Taxoids; Time Factors; Treatment Outcome | 2009 |
Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Castration; Chemotherapy, Adjuvant; Disease-Free Survival; Docetaxel; Humans; Indoles; Male; Middle Aged; Neoplasm Metastasis; Prostatic Neoplasms; Pyrroles; Quality of Life; Sunitinib; Taxoids; Time Factors; Treatment Failure | 2010 |
[Experience with sunitinib in hormone-resistant metastatic prostate cancer that is unresponsive to docetaxel].
Topics: Aged; Androgen Antagonists; Antineoplastic Agents; Compassionate Use Trials; Docetaxel; Drug Resistance, Neoplasm; Humans; Indoles; Male; Prospective Studies; Prostatic Neoplasms; Pyrroles; Sunitinib; Taxoids; Treatment Failure | 2011 |
Experience in the use of sunitinib given as a single agent in metastatic chemoresistant and castration-resistant prostate cancer patients.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Anemia; Angiogenesis Inhibitors; Castration; Diarrhea; Drug Resistance, Neoplasm; Fatigue; Hand-Foot Syndrome; Humans; Indoles; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms; Pyrroles; Sunitinib; Thrombocytopenia; Treatment Outcome | 2011 |
Sunitinib in combination with docetaxel and prednisone in chemotherapy-naive patients with metastatic, castration-resistant prostate cancer: a phase 1/2 clinical trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Humans; Indoles; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Pyrroles; Sunitinib; Taxoids | 2012 |
Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background.
Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Female; Humans; Male; Mice; Mice, Nude; Mice, SCID; Prostatic Neoplasms; Proto-Oncogene Proteins c-akt; Pyrimidines; Pyrroles; Signal Transduction; Xenograft Model Antitumor Assays | 2012 |
Multitargeted tyrosine kinase inhibition produces discordant changes between 99mTc-MDP bone scans and other disease biomarkers: analysis of a phase II study of sunitinib for metastatic castration-resistant prostate cancer.
Topics: Biomarkers, Tumor; Bone and Bones; Bone Neoplasms; Humans; Indoles; Male; Molecular Targeted Therapy; Orchiectomy; Prostate-Specific Antigen; Prostatic Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrroles; Radionuclide Imaging; Sunitinib; Technetium Tc 99m Medronate; Tomography, X-Ray Computed; Treatment Failure | 2012 |
A randomized Phase II trial of the antiangiogenic agent SU5416 in hormone-refractory prostate cancer.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Biomarkers, Tumor; Cell Line, Tumor; Dexamethasone; Dose-Response Relationship, Drug; Fibroblast Growth Factors; Humans; Indoles; Male; Middle Aged; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms; Pyrroles; Time Factors; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2004 |
Effect of statin therapy on early return of potency after nerve sparing radical retropubic prostatectomy.
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Aged; Atorvastatin; Cyclic Nucleotide Phosphodiesterases, Type 5; Denervation; Drug Therapy, Combination; Erectile Dysfunction; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Microsurgery; Middle Aged; Penile Erection; Peripheral Nerves; Piperazines; Postoperative Complications; Prospective Studies; Prostate; Prostatectomy; Prostatic Neoplasms; Purines; Pyrroles; Sildenafil Citrate; Sulfones; Vasodilator Agents | 2007 |
104 other study(ies) available for pyrroles and Prostatic Neoplasms
| Article | Year |
|---|---|
Cancer-associated fibroblast regulate proliferation and migration of prostate cancer cells through TGF-β signaling pathway.
Topics: Animals; Cancer-Associated Fibroblasts; Cell Movement; Cell Proliferation; Embryo, Nonmammalian; Gene Expression Regulation, Neoplastic; Humans; Male; Prostatic Neoplasms; Pyrazoles; Pyrroles; Receptors, Transforming Growth Factor beta; Signal Transduction; Transforming Growth Factor beta1; Tumor Cells, Cultured; Xenograft Model Antitumor Assays; Zebrafish | 2019 |
Targeting castration-resistant prostate cancer with androgen receptor antisense oligonucleotide therapy.
Topics: Animals; Antineoplastic Agents; Disease Models, Animal; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Oligonucleotides, Antisense; Phosphatidylinositol 3-Kinases; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Proto-Oncogene Proteins c-akt; Pyrimidines; Pyrroles; Receptors, Androgen; Signal Transduction; Transcriptome | 2019 |
Selective inhibition of the BD2 bromodomain of BET proteins in prostate cancer.
Topics: Animals; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Enhancer Elements, Genetic; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; Prostatic Neoplasms; Protein Domains; Pyridines; Pyrroles; Rats; Receptors, Androgen; Transcription Factors; Transcription, Genetic; Xenograft Model Antitumor Assays | 2020 |
SU6668 modulates prostate cancer progression by downregulating MTDH/AKT signaling pathway.
Topics: Angiogenesis Inhibitors; Cell Adhesion Molecules; Cell Line, Tumor; Cell Proliferation; Disease Progression; Gene Expression Regulation, Neoplastic; Humans; Indoles; Male; Membrane Proteins; Neoplasm Invasiveness; Oxindoles; Propionates; Prostatic Neoplasms; Proto-Oncogene Proteins c-akt; Pyrroles; Receptor, Fibroblast Growth Factor, Type 1; Receptor, Platelet-Derived Growth Factor beta; RNA-Binding Proteins; Signal Transduction; Vascular Endothelial Growth Factor Receptor-2 | 2017 |
A Pyrrole-Imidazole Polyamide Is Active against Enzalutamide-Resistant Prostate Cancer.
Topics: Animals; Benzamides; Cell Line, Tumor; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Imidazoles; Male; Mice; Nitriles; Nylons; Phenylthiohydantoin; Prostatic Neoplasms; Pyrroles; Receptors, Androgen; Receptors, Glucocorticoid; Xenograft Model Antitumor Assays | 2017 |
Prostate cancer: Targeting the core of resistance.
Topics: Benzamides; Humans; Male; Nitriles; Nylons; Phenylthiohydantoin; Prostatic Neoplasms; Pyrroles | 2017 |
Inhibition of the insulin-like growth factor-1 receptor potentiates acute effects of castration in a rat model for prostate cancer growth in bone.
Topics: Animals; Apoptosis; Bone Neoplasms; Cell Proliferation; Disease Models, Animal; Humans; Male; Neoplasm Staging; Phosphorylation; Prognosis; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Pyrimidines; Pyrroles; Rats; Receptor, IGF Type 1; Receptors, Somatomedin; Signal Transduction; Survival Rate; Tumor Cells, Cultured | 2017 |
Fractionated Dosing Improves Preclinical Therapeutic Index of Pyrrolobenzodiazepine-Containing Antibody Drug Conjugates.
Topics: Animals; Antibodies, Monoclonal; Benzodiazepines; Breast Neoplasms; Cell Line, Tumor; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Haplorhini; Humans; Immunoconjugates; Male; Mice; Prostatic Neoplasms; Pyrroles; Rats; Therapeutic Index; Trastuzumab; Xenograft Model Antitumor Assays | 2017 |
1-Pyrroline-5-carboxylate released by prostate Cancer cell inhibit T cell proliferation and function by targeting SHP1/cytochrome c oxidoreductase/ROS Axis.
Topics: Adenosine Triphosphate; Animals; Cell Line, Tumor; Cell Proliferation; Chromatography, Liquid; Cytochromes c; Cytokines; Disease Models, Animal; Electron Transport Chain Complex Proteins; Heterografts; Humans; Lymphocyte Activation; Male; Metabolome; Metabolomics; Mice; Mitochondria; Prostatic Neoplasms; Protein Tyrosine Phosphatase, Non-Receptor Type 6; Pyrroles; Reactive Oxygen Species; T-Lymphocytes; Tandem Mass Spectrometry | 2018 |
An electrochemical sarcosine sensor based on biomimetic recognition.
Topics: Biomarkers, Tumor; Biomimetic Materials; Biosensing Techniques; Chitosan; Electrochemical Techniques; Electrodes; Gold; Graphite; Humans; Limit of Detection; Male; Metal Nanoparticles; Particle Size; Platinum; Prostatic Neoplasms; Pyrroles; Riboflavin; Sarcosine; Sarcosine Oxidase; Surface Properties | 2019 |
Sequence specific suppression of androgen receptor-DNA binding in vivo by a Py-Im polyamide.
Topics: Androgen Receptor Antagonists; Animals; Antineoplastic Agents; Base Sequence; Binding Sites; Cell Line, Tumor; Dihydrotestosterone; Gene Expression; Humans; Imidazoles; Male; Mice; Mice, SCID; Nylons; Prostatic Neoplasms; Pyrroles; Receptors, Androgen; Response Elements; Tumor Burden; Xenograft Model Antitumor Assays | 2019 |
A novel fluorescent probe for the early detection of prostate cancer based on endogenous zinc sensing.
Topics: Animals; Biomarkers, Tumor; Cell Line, Tumor; Disease Models, Animal; Early Detection of Cancer; Fluorescent Dyes; Humans; Ions; Ketones; Male; Mice; Mice, Inbred BALB C; Prostatic Neoplasms; Pyrroles; Zinc | 2019 |
Suppression of DHT-induced paracrine stimulation of endothelial cell growth by estrogens via prostate cancer cells.
Topics: Androgens; Animals; Cell Line; Cell Line, Tumor; Cell Size; Dihydrotestosterone; Endothelial Cells; Estradiol; Estrogens; Humans; Indoles; Male; Mice; Prostate; Prostatic Neoplasms; Pyrroles; Receptors, Vascular Endothelial Growth Factor | 2013 |
TAK-441, a novel investigational smoothened antagonist, delays castration-resistant progression in prostate cancer by disrupting paracrine hedgehog signaling.
Topics: Animals; Antineoplastic Agents; Castration; Cell Line, Tumor; Cell Proliferation; Disease Progression; Hedgehog Proteins; Humans; Male; Mice; Mice, Nude; Neoplasm Transplantation; Paracrine Communication; Prostatic Neoplasms; Pyridines; Pyrroles; Receptors, G-Protein-Coupled; Smoothened Receptor; Tumor Microenvironment; Veratrum Alkaloids; Xenograft Model Antitumor Assays | 2013 |
Dual inhibition of autophagy and the AKT pathway in prostate cancer.
Topics: Adenine; Autophagy; Cell Line, Tumor; Chloroquine; Clinical Trials, Phase I as Topic; Humans; Macrolides; Male; Prostatic Neoplasms; Proto-Oncogene Proteins c-akt; Pyrimidines; Pyrroles; Signal Transduction | 2013 |
Suppression of antiviral innate immunity by sunitinib enhances oncolytic virotherapy.
Topics: Animals; Antineoplastic Agents; Carcinoma, Renal Cell; Cell Line, Tumor; Combined Modality Therapy; eIF-2 Kinase; Endoribonucleases; Female; Immunity, Innate; Indoles; Kidney Neoplasms; Male; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Mice, Nude; Oncolytic Virotherapy; Oncolytic Viruses; Prostatic Neoplasms; Pyrroles; Sunitinib; Vesiculovirus | 2013 |
Zebularine partially reverses GST methylation in prostate cancer cells and restores sensitivity to the DNA minor groove binder brostallicin.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cytidine; DNA Methylation; Gene Expression Regulation, Neoplastic; Glutathione Transferase; Guanidines; Humans; Male; Mice; Prostatic Neoplasms; Pyrroles; Random Allocation; Xenograft Model Antitumor Assays | 2013 |
Inhibition of proliferation and induction of autophagy by atorvastatin in PC3 prostate cancer cells correlate with downregulation of Bcl2 and upregulation of miR-182 and p21.
Topics: Atorvastatin; Autophagy; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; Diterpenes; Down-Regulation; Gene Expression Regulation, Neoplastic; Heptanoic Acids; Humans; Male; MicroRNAs; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Pyrroles; Up-Regulation | 2013 |
Atorvastatin inhibited Rho-associated kinase 1 (ROCK1) and focal adhesion kinase (FAK) mediated adhesion and differentiation of CD133+CD44+ prostate cancer stem cells.
Topics: AC133 Antigen; Aged; Antigens, CD; Antineoplastic Agents; Atorvastatin; Cell Adhesion; Cell Differentiation; Focal Adhesion Kinase 1; Glycoproteins; Heptanoic Acids; Humans; Hyaluronan Receptors; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Neoplastic Stem Cells; Peptides; Prostate; Prostatic Neoplasms; Pyrroles; rho-Associated Kinases; Tumor Cells, Cultured | 2013 |
Inhibition of IL-6 expression in LNCaP prostate cancer cells by a combination of atorvastatin and celecoxib.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Atorvastatin; Castration; Celecoxib; Cell Survival; Cyclooxygenase 2 Inhibitors; Disease Progression; Enzyme Inhibitors; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inhibitor of Apoptosis Proteins; Interleukin-6; Male; Mice; Mice, SCID; Prostatic Neoplasms; Pyrazoles; Pyrroles; Sulfonamides; Survivin; Xenograft Model Antitumor Assays | 2014 |
Probing for DNA methylation with a voltammetric DNA detector.
Topics: Base Sequence; Biomarkers, Tumor; Biosensing Techniques; DNA; DNA Methylation; DNA, Single-Stranded; Electrochemical Techniques; Electrochemistry; Glutathione S-Transferase pi; Humans; Male; Microelectrodes; Nucleic Acid Hybridization; Platinum; Polymers; Promoter Regions, Genetic; Prostatic Neoplasms; Pyrroles; Reproducibility of Results; Sensitivity and Specificity; Static Electricity | 2014 |
Atorvastatin prevents ATP-driven invasiveness via P2X7 and EHBP1 signaling in PTEN-expressing prostate cancer cells.
Topics: Adenosine Triphosphate; Atorvastatin; Blotting, Western; Carrier Proteins; Cell Movement; Cell Nucleus; Cell Proliferation; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunoenzyme Techniques; Male; Neoplasm Invasiveness; Phosphorylation; Prostatic Neoplasms; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Pyrroles; Receptors, Purinergic P2X7; RNA, Small Interfering; Signal Transduction; Tumor Cells, Cultured | 2014 |
Corticotropin-releasing hormone receptors mediate apoptosis via cytosolic calcium-dependent phospholipase A₂ and migration in prostate cancer cell RM-1.
Topics: Animals; Apoptosis; bcl-2-Associated X Protein; Cell Line, Tumor; Cell Movement; Corticotropin-Releasing Hormone; Dactinomycin; Down-Regulation; HEK293 Cells; Humans; Interleukin-1beta; Male; Mice; Mitomycin; Peptide Fragments; Phospholipases A2; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Pyrimidines; Pyrroles; Receptors, Corticotropin-Releasing Hormone; RNA Interference; RNA, Messenger; RNA, Small Interfering; Thapsigargin; Tumor Necrosis Factor-alpha; Up-Regulation; Urocortins | 2014 |
A C-14 labeled Py-Im polyamide localizes to a subcutaneous prostate cancer tumor.
Topics: Animals; Carbon Radioisotopes; Heterografts; Imidazoles; Injections, Subcutaneous; Male; Mice; Molecular Structure; Neoplasm Transplantation; Nylons; Prostatic Neoplasms; Pyrroles; Tissue Distribution | 2014 |
Combination of Lipitor and Celebrex inhibits prostate cancer VCaP cells in vitro and in vivo.
Topics: Animals; Anticholesteremic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Atorvastatin; Celecoxib; Cell Growth Processes; Cell Line, Tumor; Cyclooxygenase 2 Inhibitors; Heptanoic Acids; Humans; Male; Mice; Mice, SCID; Prostatic Neoplasms; Pyrazoles; Pyrroles; Sulfonamides; Xenograft Model Antitumor Assays | 2014 |
In vivo quantitative phosphoproteomic profiling identifies novel regulators of castration-resistant prostate cancer growth.
Topics: Androgens; Animals; Cell Line, Tumor; Cell Proliferation; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Phosphorylation; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Proteome; Proteomics; Pyrazoles; Pyrroles; Receptors, Androgen; Signal Transduction | 2015 |
Pyrrole-imidazole polyamide targeted to break fusion sites in TMPRSS2 and ERG gene fusion represses prostate tumor growth.
Topics: Animals; Cell Line, Tumor; Cell Movement; Cell Proliferation; Gene Fusion; Humans; Imidazoles; Male; Mice; Nylons; Prostatic Neoplasms; Pyrroles; Serine Endopeptidases; Trans-Activators; Transcriptional Regulator ERG | 2014 |
High Efficacy of Combination Therapy Using PI3K/AKT Inhibitors with Androgen Deprivation in Prostate Cancer Preclinical Models.
Topics: Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Castration; Cell Line, Tumor; Cell Proliferation; Chromones; Humans; Male; Phosphoinositide-3 Kinase Inhibitors; Prostatic Neoplasms; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Pyrimidines; Pyrroles; Receptors, Androgen; Signal Transduction; Treatment Outcome; Xenograft Model Antitumor Assays | 2015 |
Tumor xenograft uptake of a pyrrole-imidazole (Py-Im) polyamide varies as a function of cell line grafted.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Collagen; Drug Combinations; Humans; Imidazoles; Laminin; Lung Neoplasms; Male; Mice, Inbred BALB C; Nylons; Prostatic Neoplasms; Proteoglycans; Pyrroles; Tissue Distribution; Xenograft Model Antitumor Assays | 2014 |
Complex impacts of PI3K/AKT inhibitors to androgen receptor gene expression in prostate cancer cells.
Topics: Androstadienes; Cell Line, Tumor; Chromones; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Male; Molecular Targeted Therapy; Morpholines; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Prostatic Neoplasms; Proto-Oncogene Proteins c-akt; Pyrimidines; Pyrroles; Receptors, Androgen; RNA Splicing; RNA Stability; Transcription Initiation, Genetic; Wortmannin | 2014 |
EGFR and IGF-1R in regulation of prostate cancer cell phenotype and polarity: opposing functions and modulation by T-cadherin.
Topics: Cadherins; Cell Line, Tumor; Cell Movement; Cell Nucleus; Cell Survival; Collagen; Drug Combinations; ErbB Receptors; Gefitinib; Gene Silencing; Golgi Apparatus; Humans; Laminin; Male; Neoplasm Invasiveness; Phenotype; Phosphorylation; Prostate; Prostatic Neoplasms; Proteoglycans; Pyrimidines; Pyrroles; Quinazolines; Receptor, IGF Type 1 | 2015 |
Differential sensitivity of prostate tumor derived endothelial cells to sorafenib and sunitinib.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Biomarkers; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Endothelial Cells; Humans; Indoles; Male; Middle Aged; Neoplasm Grading; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Phosphorylation; Prostatic Neoplasms; Protein Kinase Inhibitors; Pyrroles; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor Receptor-2 | 2014 |
Clusterin facilitates stress-induced lipidation of LC3 and autophagosome biogenesis to enhance cancer cell survival.
Topics: Animals; Apoptosis; Autophagy; Autophagy-Related Proteins; Cell Line, Tumor; Cell Survival; Clusterin; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Lipid Metabolism; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Nude; Microtubule-Associated Proteins; Phagosomes; Prostatic Neoplasms; Pyrimidines; Pyrroles; Signal Transduction; Thionucleotides; Ubiquitin-Conjugating Enzymes; Xenograft Model Antitumor Assays | 2014 |
Prostatic angiogenic responses in late life: antiangiogenic therapy influences and relation with the glandular microenvironment in the transgenic adenocarcinoma of mouse prostate (TRAMP) model.
Topics: 5-alpha Reductase Inhibitors; Adenocarcinoma; Angiogenesis Inhibitors; Animals; Blotting, Western; Cyclohexanes; Disease Models, Animal; Endostatins; Fibroblast Growth Factor 2; Finasteride; Hypoxia-Inducible Factor 1, alpha Subunit; Immunohistochemistry; Indoles; Male; Mice; Mice, Transgenic; Neovascularization, Pathologic; O-(Chloroacetylcarbamoyl)fumagillol; Prostatic Neoplasms; Pyrroles; Sesquiterpenes; Tumor Microenvironment; Vascular Endothelial Growth Factor A | 2015 |
Mechanistic rationale for MCL1 inhibition during androgen deprivation therapy.
Topics: Animals; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Humans; Indoles; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Myeloid Cell Leukemia Sequence 1 Protein; Prostatic Neoplasms; Pyrroles; Random Allocation; Receptors, Androgen; Risk Factors; Transfection; Xenograft Model Antitumor Assays | 2015 |
Sunitinib reduces tumor hypoxia and angiogenesis, and radiosensitizes prostate cancer stem-like cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Hypoxia; Cell Line, Tumor; Cell Proliferation; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Indoles; Male; Mice; Neoplastic Stem Cells; Neovascularization, Pathologic; Prostate; Prostatic Neoplasms; Pyrroles; Sunitinib; Treatment Outcome; Xenograft Model Antitumor Assays | 2015 |
Targeting cells of the myeloid lineage attenuates pain and disease progression in a prostate model of bone cancer.
Topics: Aminopyridines; Analgesics; Animals; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Bone and Bones; Bone Neoplasms; Cell Line, Tumor; Disease Models, Animal; Disease Progression; Dogs; Formaldehyde; Male; Mice; Mice, Nude; Neoplasm Transplantation; Pain; Pain Measurement; Prostatic Neoplasms; Protein Kinases; Pyrroles; Rats; Rats, Sprague-Dawley | 2015 |
Tumor Repression of VCaP Xenografts by a Pyrrole-Imidazole Polyamide.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; DNA; DNA Damage; DNA Topoisomerases; Gene Expression Regulation; Humans; Imidazoles; Male; Mice; Nylons; Oncogene Proteins, Fusion; Prostatic Neoplasms; Protein Binding; Pyrroles; Receptors, Androgen; Sequence Analysis, RNA; Transplantation, Heterologous | 2015 |
p21CIP1 Induces Apoptosis via Binding to BCL2 in LNCaP Prostate Cancer Cells Treated with MCS-C3, A Novel Carbocyclic Analog of Pyrrolopyrimidine.
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Humans; Male; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Pyrimidines; Pyrroles; Signal Transduction; Transfection | 2016 |
Effects of a novel carbocyclic analog of pyrrolo[2,3-d]pyrimidine nucleoside on pleiotropic induction of cell death in prostate cancer cells with different androgen responsiveness.
Topics: Apoptosis; Caspase 3; Cell Cycle Checkpoints; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p21; Humans; Male; Poly(ADP-ribose) Polymerases; Prostatic Neoplasms; Pyridines; Pyrimidine Nucleosides; Pyrroles; Receptors, Androgen; Up-Regulation | 2016 |
Efficacy of targeted AKT inhibition in genetically engineered mouse models of PTEN-deficient prostate cancer.
Topics: Animals; Antineoplastic Agents; Disease Models, Animal; Drug Screening Assays, Antitumor; Genetic Engineering; Male; Mice; Mice, Knockout; Prostatic Neoplasms; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Pyrimidines; Pyrroles; Tumor Suppressor Protein p53 | 2016 |
P-Rex1 Promotes Resistance to VEGF/VEGFR-Targeted Therapy in Prostate Cancer.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Animals; Bevacizumab; Carcinogenesis; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Guanine Nucleotide Exchange Factors; Humans; Indoles; Inhibitory Concentration 50; Male; Mice, Inbred NOD; Mice, SCID; Molecular Targeted Therapy; Neoplastic Stem Cells; Prostatic Neoplasms; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sunitinib; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2016 |
Discovery of New Aminosubstituted Pyrrolopyrimidines with Antiproliferative Activity Against Breast Cancer Cells and Investigation of their Effect Towards the PI3Kα Enzyme.
Topics: Amination; Antineoplastic Agents; Breast; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Class I Phosphatidylinositol 3-Kinases; Drug Design; Drug Screening Assays, Antitumor; Female; Humans; Male; Molecular Docking Simulation; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Prostate; Prostatic Neoplasms; Protein Kinase Inhibitors; Pyrimidines; Pyrroles | 2017 |
Combination treatment of prostate cancer with FGF receptor and AKT kinase inhibitors.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Extracellular Signal-Regulated MAP Kinases; Humans; Male; Mice, SCID; Phosphorylation; Piperazines; Prostatic Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrazoles; Pyrimidines; Pyrroles; Receptor, Fibroblast Growth Factor, Type 1; Signal Transduction; STAT3 Transcription Factor; Tumor Burden; Xenograft Model Antitumor Assays | 2017 |
Upregulation of long non-coding RNA PlncRNA-1 promotes proliferation and induces epithelial-mesenchymal transition in prostate cancer.
Topics: Animals; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Proliferation; Disease Models, Animal; Epithelial-Mesenchymal Transition; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Gene Silencing; Humans; Male; Mice; Prostatic Neoplasms; Pyrazoles; Pyrroles; RNA, Long Noncoding; Signal Transduction; Transforming Growth Factor beta1; Xenograft Model Antitumor Assays | 2017 |
4-(Anilino)pyrrole-2-carboxamides: Novel non-steroidal/non-anilide type androgen antagonists effective upon human prostate tumor LNCaP cells with mutated nuclear androgen receptor.
Topics: Androgen Antagonists; Androgen Receptor Antagonists; Cell Line, Tumor; Humans; Male; Mutation; Prostate-Specific Antigen; Prostatic Neoplasms; Protein Binding; Pyrroles; Receptors, Androgen | 2008 |
Sunitinib malate (SU-11248) alone or in combination with low-dose docetaxel inhibits the growth of DU-145 prostate cancer xenografts.
Topics: Administration, Oral; Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Indoles; Infusions, Intravenous; Male; Mice; Mice, Nude; Prostatic Neoplasms; Pyrroles; Sunitinib; Taxoids; Xenograft Model Antitumor Assays | 2008 |
The influence of statin medications on prostate-specific antigen levels.
Topics: Aged; Atorvastatin; Biomarkers, Tumor; Cholesterol, HDL; Cholesterol, LDL; Early Diagnosis; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Indoles; Linear Models; Longitudinal Studies; Lovastatin; Male; Middle Aged; Multivariate Analysis; Pravastatin; Prostate-Specific Antigen; Prostatic Neoplasms; Pyrroles; Risk Assessment; Simvastatin; Veterans | 2008 |
FBA-TPQ, a novel marine-derived compound as experimental therapy for prostate cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; Prostate-Specific Antigen; Prostatic Neoplasms; Pyrroles; Quinolones; Receptors, Androgen | 2010 |
Cyclic pyrrole-imidazole polyamides targeted to the androgen response element.
Topics: Base Sequence; Cell Line, Tumor; Cell Membrane Permeability; DNA; Drug Delivery Systems; Drug Stability; Hot Temperature; Humans; Imidazoles; Macrocyclic Compounds; Male; Models, Molecular; Nylons; Prostatic Neoplasms; Pyrroles; Receptors, Androgen; Response Elements; Solutions | 2009 |
Regulation of steroid 5-alpha reductase type 2 (Srd5a2) by sterol regulatory element binding proteins and statin.
Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; Animals; Atorvastatin; Azetidines; Cell Line, Tumor; Ezetimibe; Gene Expression Regulation, Enzymologic; Heptanoic Acids; Hydroxymethylglutaryl CoA Reductases; Hypercholesterolemia; Liver; Lovastatin; Male; Mice; Promoter Regions, Genetic; Prostate; Prostatic Neoplasms; Pyrroles; Sterol Regulatory Element Binding Protein 2; Transfection | 2009 |
Inhibition of epithelial to mesenchymal transition in metastatic prostate cancer cells by the novel proteasome inhibitor, NPI-0052: pivotal roles of Snail repression and RKIP induction.
Topics: Cell Differentiation; Cell Line, Tumor; Cell Movement; Epithelial Cells; Gene Expression Regulation, Neoplastic; Humans; Lactones; Male; Mesoderm; Neoplasm Invasiveness; Neoplasm Metastasis; NF-kappa B; Phosphatidylethanolamine Binding Protein; Prostatic Neoplasms; Protease Inhibitors; Proteasome Inhibitors; Pyrroles; Snail Family Transcription Factors; Transcription Factors | 2009 |
Biochemical and pathological response of prostate cancer in a patient with metastatic renal cell carcinoma on sunitinib treatment.
Topics: Benzamides; Carcinoma, Renal Cell; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Kidney Neoplasms; Male; Middle Aged; Piperazines; Prostate-Specific Antigen; Prostatic Neoplasms; Pyrimidines; Pyrroles; Sunitinib | 2009 |
Pivotal roles of snail inhibition and RKIP induction by the proteasome inhibitor NPI-0052 in tumor cell chemoimmunosensitization.
Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Cisplatin; Humans; Lactones; Leupeptins; Male; Melanoma; Membrane Potential, Mitochondrial; NF-kappa B; Phosphatidylethanolamine Binding Protein; Prostatic Neoplasms; Proteasome Inhibitors; Proto-Oncogene Proteins c-raf; Pyrazines; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Snail Family Transcription Factors; TNF-Related Apoptosis-Inducing Ligand; Transcription Factors; Transfection; Tumor Cells, Cultured | 2009 |
Proteasome inhibitors activate autophagy as a cytoprotective response in human prostate cancer cells.
Topics: Animals; Autophagy; Autophagy-Related Protein 5; Autophagy-Related Protein 7; Boronic Acids; Bortezomib; Cell Line; Cell Line, Tumor; Cell Survival; Humans; Immunoblotting; Lactones; Lysosomes; Male; Microscopy, Electron, Transmission; Microtubule-Associated Proteins; Phagosomes; Prostatic Neoplasms; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Ubiquitin-Activating Enzymes | 2010 |
About tyrosine kinase inhibitors (TKIs) in prostate cancer: where do we go from here?
Topics: Antineoplastic Agents; Benzenesulfonates; Biomarkers, Tumor; Clinical Trials, Phase II as Topic; Humans; Indoles; Male; Niacinamide; Phenylurea Compounds; Prostate-Specific Antigen; Prostatic Neoplasms; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib | 2010 |
Atorvastatin and celecoxib in combination inhibits the progression of androgen-dependent LNCaP xenograft prostate tumors to androgen independence.
Topics: Androgens; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Atorvastatin; Blotting, Western; Celecoxib; Cell Proliferation; Disease Progression; Gene Expression; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunohistochemistry; Male; Mice; Mice, SCID; Neoplasms, Hormone-Dependent; NF-kappa B; Prostatic Neoplasms; Pyrazoles; Pyrroles; Sulfonamides; Xenograft Model Antitumor Assays | 2010 |
Application of T cell-based transcriptomics to identify three candidate biomarkers for monitoring anti-TGFbetaR therapy.
Topics: Biomarkers; Breast Neoplasms; Cells, Cultured; Dose-Response Relationship, Drug; Female; Gene Expression Profiling; Gene Expression Regulation; Humans; Male; Monitoring, Physiologic; Oligonucleotide Array Sequence Analysis; Ovarian Neoplasms; Prostatic Neoplasms; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pyrazoles; Pyrroles; Receptor, Transforming Growth Factor-beta Type I; Receptors, Transforming Growth Factor beta; T-Lymphocytes; Transcription, Genetic | 2010 |
Three cases of severe ulcerative esophagitis induced by SUTENT®.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Esophagitis; Gastrointestinal Hemorrhage; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Prostatic Neoplasms; Pyrroles; Sunitinib; Ulcer | 2012 |
Novel microtubule-targeting agents, pyrrolo-1,5-benzoxazepines, induce cell cycle arrest and apoptosis in prostate cancer cells.
Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Humans; Inhibitory Concentration 50; Male; Models, Biological; Oxazepines; Prostatic Neoplasms; Pyrroles; Tubulin Modulators | 2010 |
[Comment to: "Experience with sunitinib in hormone-resistant metastatic prostate cancer that is unresponsive to docetaxel"].
Topics: Androgen Antagonists; Antineoplastic Agents; Docetaxel; Drug Resistance, Neoplasm; Humans; Indoles; Male; Prostatic Neoplasms; Pyrroles; Sunitinib; Taxoids; Treatment Failure | 2011 |
Atorvastatin activates heme oxygenase-1 at the stress response elements.
Topics: Apoptosis; Atorvastatin; Breast Neoplasms; Cell Line, Tumor; Female; Heme Oxygenase-1; Heptanoic Acids; Humans; Male; Oxidative Stress; Polyisoprenyl Phosphates; Promoter Regions, Genetic; Prostatic Neoplasms; Pyrroles; Signal Transduction; Transcriptional Activation; Up-Regulation | 2012 |
Statins and prostate cancer diagnosis and grade in a veterans population.
Topics: Aged; Aged, 80 and over; Anticarcinogenic Agents; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Biomarkers, Tumor; Cholesterol; Confounding Factors, Epidemiologic; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Indoles; Lipids; Lovastatin; Male; Middle Aged; Multivariate Analysis; New England; Pravastatin; Proportional Hazards Models; Prostatic Neoplasms; Pyrroles; Risk Assessment; Severity of Illness Index; Simvastatin; Veterans | 2011 |
Vasculatures in tumors growing from preirradiated tissues: formed by vasculogenesis and resistant to radiation and antiangiogenic therapy.
Topics: Angiogenesis Inhibitors; Animals; Bone Marrow Transplantation; Cell Aggregation; Cell Hypoxia; Cell Line, Tumor; Coloring Agents; Drug Resistance, Neoplasm; Endothelial Cells; Green Fluorescent Proteins; Indoles; Macrophages; Male; Mice; Mice, Inbred C57BL; Neoplasm Recurrence, Local; Neoplasms, Radiation-Induced; Neovascularization, Pathologic; Nitroimidazoles; Prostatic Neoplasms; Pyrroles; Radiation Dosage; Radiation Tolerance; Radiation-Sensitizing Agents; Salvage Therapy; Sunitinib; Tumor Burden; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2011 |
Atorvastatin induces autophagy in prostate cancer PC3 cells through activation of LC3 transcription.
Topics: Atorvastatin; Autophagy; Cell Growth Processes; Diterpenes; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; MAP Kinase Signaling System; Microtubule-Associated Proteins; Mitogen-Activated Protein Kinases; Phosphatidylinositol 3-Kinases; Prostatic Neoplasms; Pyrroles; TOR Serine-Threonine Kinases; Transcription, Genetic; Transcriptional Activation | 2011 |
Insulin-like growth factor-type 1 receptor inhibitor NVP-AEW541 enhances radiosensitivity of PTEN wild-type but not PTEN-deficient human prostate cancer cells.
Topics: Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; DNA Breaks, Double-Stranded; DNA Repair; Down-Regulation; Humans; Male; Neoplasm Proteins; Prostatic Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Pyrimidines; Pyrroles; Radiation Tolerance; Radiation-Sensitizing Agents; Receptor, IGF Type 1 | 2011 |
Interleukin-6: a potential biomarker of resistance to multitargeted receptor tyrosine kinase inhibitors in castration-resistant prostate cancer.
Topics: Animals; Apoptosis; Biomarkers, Tumor; Cell Line, Tumor; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Indazoles; Indoles; Interleukin-6; Male; Mice; Mice, Inbred C57BL; Mice, SCID; Neoplasm Transplantation; Prostatic Neoplasms; Pyrimidines; Pyrroles; Receptor Protein-Tyrosine Kinases; RNA, Messenger; Sulfonamides; Sunitinib | 2011 |
Design, synthesis, and biological evaluation of 4-phenylpyrrole derivatives as novel androgen receptor antagonists.
Topics: Amino Acid Substitution; Androgen Receptor Antagonists; Animals; Antineoplastic Agents; Cell Line, Tumor; Drug Design; Drug Resistance, Neoplasm; Humans; Male; Mice; Mice, Inbred ICR; Mice, Nude; Mutation; Prostatic Neoplasms; Pyrroles; Receptors, Androgen; Transplantation, Heterologous | 2012 |
Effect of transforming growth factor beta (TGF-β) receptor I kinase inhibitor on prostate cancer bone growth.
Topics: Animals; Antineoplastic Agents; Bone and Bones; Bone Neoplasms; Cell Line, Tumor; Cell Proliferation; Femur; Humans; Male; Mice; Osteoblasts; Prostatic Neoplasms; Protein Serine-Threonine Kinases; Pyrazoles; Pyrroles; Receptor, Transforming Growth Factor-beta Type I; Receptors, Transforming Growth Factor beta; Transforming Growth Factor beta1; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2012 |
Cell killing and radiosensitizing effects of atorvastatin in PC3 prostate cancer cells.
Topics: Atorvastatin; Autophagy; Cell Line, Tumor; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Heptanoic Acids; Humans; Male; Prostatic Neoplasms; Pyrroles; Radiation Tolerance; Radiation-Sensitizing Agents | 2012 |
Modulation of Akt/mTOR signaling overcomes sunitinib resistance in renal and prostate cancer cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cytokines; Drug Resistance, Neoplasm; Humans; Indoles; Kidney Neoplasms; Male; Mice; Mice, SCID; Prostatic Neoplasms; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Pyrroles; Signal Transduction; Sunitinib; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2012 |
The preventative effects of sunitinib malate observed in the course from non-castration to castration LNCaP xenograft prostate tumors.
Topics: Androgens; Animals; Apoptosis; Caspase 3; Cell Line, Tumor; Cell Proliferation; Humans; Indoles; Ki-67 Antigen; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neovascularization, Pathologic; Orchiectomy; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Pyrroles; Receptors, Platelet-Derived Growth Factor; Sunitinib; Vascular Endothelial Growth Factor Receptor-2; von Willebrand Factor; Xenograft Model Antitumor Assays | 2012 |
Preclinical evaluation of sunitinib, a multi-tyrosine kinase inhibitor, as a radiosensitizer for human prostate cancer.
Topics: Animals; Apoptosis; Blotting, Western; Cell Proliferation; Fluorescent Antibody Technique; fms-Like Tyrosine Kinase 3; Humans; Indoles; Male; Mice; Mice, Nude; Prostatic Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrroles; Radiation-Sensitizing Agents; Receptor, Platelet-Derived Growth Factor beta; Sunitinib; Tumor Cells, Cultured; Tumor Stem Cell Assay; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2012 |
Potent, selective, and orally bioavailable inhibitors of the mammalian target of rapamycin kinase domain exhibiting single agent antiproliferative activity.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Biological Availability; Cell Line, Tumor; Drug Screening Assays, Antitumor; Female; Humans; Male; Mechanistic Target of Rapamycin Complex 1; Mechanistic Target of Rapamycin Complex 2; Mice; Mice, Nude; Molecular Docking Simulation; Multiprotein Complexes; Neoplasm Transplantation; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Prostatic Neoplasms; Pyrimidines; Pyrroles; Quinazolines; Structure-Activity Relationship; TOR Serine-Threonine Kinases; Transplantation, Heterologous | 2012 |
Chemical biology drug sensitivity screen identifies sunitinib as synergistic agent with disulfiram in prostate cancer cells.
Topics: Apoptosis; Cadherins; Cell Line, Tumor; Cell Movement; Cell Survival; Disulfiram; Drug Screening Assays, Antitumor; Drug Synergism; High-Throughput Screening Assays; Humans; Indoles; Male; Neoplasm Invasiveness; Oncogene Proteins, Fusion; Prostate-Specific Antigen; Prostatic Neoplasms; Pyrroles; Receptors, Androgen; Signal Transduction; Sunitinib | 2012 |
Blocked autophagy using lysosomotropic agents sensitizes resistant prostate tumor cells to the novel Akt inhibitor AZD5363.
Topics: Autophagy; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Chloroquine; Drug Resistance, Neoplasm; Drug Synergism; Humans; Lysosomes; Male; Oncogene Protein v-akt; Prostatic Neoplasms; PTEN Phosphohydrolase; Pyrimidines; Pyrroles; Signal Transduction | 2013 |
Antitumor activity of a pyrrole-imidazole polyamide.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Dose-Response Relationship, Drug; Humans; Imidazoles; Immunoblotting; Interleukin Receptor Common gamma Subunit; Male; Mice; Mice, Inbred C57BL; Mice, Inbred NOD; Mice, Knockout; Mice, SCID; Nylons; Prostatic Neoplasms; Proteasome Inhibitors; Protein Subunits; Pyrroles; RNA Polymerase II; Signal Transduction; Time Factors; Transcription, Genetic; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2013 |
Growth inhibitory effects of the dual ErbB1/ErbB2 tyrosine kinase inhibitor PKI-166 on human prostate cancer xenografts.
Topics: Androgens; Animals; Cell Division; ErbB Receptors; Growth Inhibitors; Humans; Male; Mice; Mice, SCID; Prostatic Neoplasms; Pyrimidines; Pyrroles; Receptor, ErbB-2; Signal Transduction; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2002 |
Blockade of epidermal growth factor receptor signaling in tumor cells and tumor-associated endothelial cells for therapy of androgen-independent human prostate cancer growing in the bone of nude mice.
Topics: Administration, Oral; Animals; Antineoplastic Agents, Phytogenic; Blotting, Western; Bone and Bones; Bone Neoplasms; Dose-Response Relationship, Drug; Endothelial Growth Factors; Endothelium, Vascular; ErbB Receptors; Fibroblast Growth Factor 2; Immunohistochemistry; In Situ Nick-End Labeling; Intercellular Signaling Peptides and Proteins; Interleukin-8; Lymphokines; Male; Mice; Mice, Nude; Microscopy, Fluorescence; Neoplasm Metastasis; Neoplasm Transplantation; Paclitaxel; Phosphorylation; Platelet Endothelial Cell Adhesion Molecule-1; Proliferating Cell Nuclear Antigen; Prostatic Neoplasms; Pyrimidines; Pyrroles; Signal Transduction; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2003 |
ErbB1 and prostate cancer: ErbB1 activity is essential for androgen-induced proliferation and protection from the apoptotic effects of LY294002.
Topics: Androgens; Apoptosis; Cell Division; Chromones; Drug Interactions; Enzyme Inhibitors; Epidermal Growth Factor; ErbB Receptors; Humans; Ligands; Male; Morpholines; Prostatic Neoplasms; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Tumor Cells, Cultured | 2003 |
SU5416 and SU6668 attenuate the angiogenic effects of radiation-induced tumor cell growth factor production and amplify the direct anti-endothelial action of radiation in vitro.
Topics: Angiogenesis Inhibitors; Cell Division; Cells, Cultured; Dose-Response Relationship, Radiation; Endothelial Growth Factors; Endothelium, Vascular; Fibroblast Growth Factor 2; Humans; Indoles; Intercellular Signaling Peptides and Proteins; Kinetics; Lymphokines; Male; Neoplasm Invasiveness; Neovascularization, Pathologic; Oxindoles; Particle Accelerators; Propionates; Prostatic Neoplasms; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction; Tumor Cells, Cultured; Umbilical Veins; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors; X-Rays | 2003 |
SU5416 selectively impairs angiogenesis to induce prostate cancer-specific apoptosis.
Topics: Angiogenesis Inhibitors; Animals; Apoptosis; Cell Differentiation; Disease Models, Animal; Disease Progression; Drug Evaluation, Preclinical; Gene Expression Regulation, Neoplastic; Indoles; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Microcirculation; Neovascularization, Pathologic; Prostatic Neoplasms; Protein-Tyrosine Kinases; Pyrroles; Up-Regulation; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2 | 2003 |
Pyrrolopyrimidine c-Src inhibitors reduce growth, adhesion, motility and invasion of prostate cancer cells in vitro.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Cell Adhesion; Cell Division; Cell Movement; Cell Size; CSK Tyrosine-Protein Kinase; Drug Screening Assays, Antitumor; Humans; Male; Matrix Metalloproteinases; Neoplasm Invasiveness; Prostatic Neoplasms; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; src-Family Kinases; Tumor Cells, Cultured | 2003 |
Pharmacological inhibition of FGF receptor signaling inhibits LNCaP prostate tumor growth, promatrilysin, and PSA expression.
Topics: Animals; Carcinoma; Enzyme Precursors; Humans; Male; Metalloendopeptidases; Mice; Mice, Nude; Neoplasm Transplantation; Prostate-Specific Antigen; Prostatic Neoplasms; Pyrroles; Receptors, Fibroblast Growth Factor; Transplantation, Heterologous; Tumor Cells, Cultured | 2003 |
Combined therapy with direct and indirect angiogenesis inhibition results in enhanced antiangiogenic and antitumor effects.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Animals; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Division; Cell Movement; Cell Survival; Drug Synergism; Endostatins; Endothelium, Vascular; Female; Glioblastoma; Humans; Indoles; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Mice, SCID; Neoplasms; Neovascularization, Pathologic; Prostatic Neoplasms; Pyrroles; Ultrasonography; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2003 |
Effective treatment of experimental androgen sensitive and androgen independent intraosseous prostate cancer with targeted cytotoxic somatostatin analogue AN-238.
Topics: Androgens; Animals; Bone Neoplasms; Cell Line, Tumor; Cytotoxins; Doxorubicin; Drug Carriers; Humans; Male; Mice; Mice, Nude; Octreotide; Prostatic Neoplasms; Pyrroles; Somatostatin | 2004 |
PP2A inhibitors, harzianic acid and related compounds produced by fungus strain F-1531.
Topics: Enzyme Inhibitors; Fermentation; Fungi; Humans; Hydroxybutyrates; Male; Phosphoprotein Phosphatases; Prostatic Neoplasms; Pyrroles | 2004 |
Simultaneous blockade of platelet-derived growth factor-receptor and epidermal growth factor-receptor signaling and systemic administration of paclitaxel as therapy for human prostate cancer metastasis in bone of nude mice.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Bone Neoplasms; Cell Division; Enzyme Inhibitors; ErbB Receptors; Humans; Imatinib Mesylate; In Situ Nick-End Labeling; Male; Mice; Mice, Nude; Paclitaxel; Phosphorylation; Piperazines; Platelet Endothelial Cell Adhesion Molecule-1; Prostatic Neoplasms; Pyrimidines; Pyrroles; Receptors, Platelet-Derived Growth Factor; Substrate Specificity; Xenograft Model Antitumor Assays | 2004 |
HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability.
Topics: Animals; Chlorocebus aethiops; COS Cells; DNA, Neoplasm; ErbB Receptors; Humans; Male; Prostatic Neoplasms; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Pyrimidines; Pyrroles; Receptor, ErbB-2; Receptors, Androgen; RNA, Small Interfering; Signal Transduction; Transfection; Tumor Cells, Cultured | 2004 |
Combined antiangiogenic and immune therapy of prostate cancer.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; CD3 Complex; Cell Line, Tumor; Immunoglobulin G; Immunotherapy; Indoles; Male; Mice; Oxindoles; Propionates; Prostatic Neoplasms; Protein-Tyrosine Kinases; Pyrroles; Recombinant Fusion Proteins; T-Lymphocytes | 2005 |
Inhibition of human experimental prostate cancers by a targeted cytotoxic luteinizing hormone-releasing hormone analog AN-207.
Topics: Androgens; Animals; Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Disease Progression; Doxorubicin; Gonadotropin-Releasing Hormone; Humans; Male; Mice; Mice, Nude; Neoplasm Transplantation; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Pyrroles; Receptors, LHRH; RNA, Messenger; Transplantation, Heterologous; Triptorelin Pamoate | 2006 |
Statins, especially atorvastatin, may favorably influence clinical presentation and biochemical progression-free survival after brachytherapy for clinically localized prostate cancer.
Topics: Aged; Atorvastatin; Brachytherapy; Disease Progression; Disease-Free Survival; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Prostatic Neoplasms; Pyrroles | 2005 |
Statins, especially atorvastatin, may improve survival following brachytherapy for clinically localized prostate cancer.
Topics: Aged; Atorvastatin; Biopsy; Brachytherapy; Cause of Death; Chemotherapy, Adjuvant; Chi-Square Distribution; Disease-Free Survival; Fatty Acids, Monounsaturated; Fluvastatin; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Male; Neoplasm Staging; Pravastatin; Proportional Hazards Models; Prostatic Neoplasms; Pyrroles; Retrospective Studies; Simvastatin; Survival Analysis | 2006 |
Heparin affin regulatory peptide/pleiotrophin mediates fibroblast growth factor 2 stimulatory effects on human prostate cancer cells.
Topics: Carrier Proteins; Cell Culture Techniques; Cell Division; Cell Line, Tumor; Cell Movement; Cytokines; Enzyme Inhibitors; Fibroblast Growth Factor 2; Gene Expression Regulation, Neoplastic; Genes, Reporter; Humans; Hydrogen Peroxide; Immunologic Factors; Kinetics; Luciferases; Male; Models, Biological; Oxidants; Promoter Regions, Genetic; Prostatic Neoplasms; Pyrroles; Recombinant Proteins; RNA, Messenger | 2006 |
Nerve growth factor enhances voltage-gated Na+ channel activity and Transwell migration in Mat-LyLu rat prostate cancer cell line.
Topics: Animals; Carbazoles; Cell Line, Tumor; Cell Movement; Cyclic AMP-Dependent Protein Kinases; Disease Models, Animal; Dose-Response Relationship, Drug; Electrophysiology; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Indole Alkaloids; Indoles; Male; NAV1.7 Voltage-Gated Sodium Channel; Nerve Growth Factor; Patch-Clamp Techniques; Prostatic Neoplasms; Pyrroles; Rats; Receptors, Nerve Growth Factor; RNA, Messenger; Sodium Channels; Time Factors; Up-Regulation | 2007 |
Supra-additive antitumor effect of sunitinib malate (SU11248, Sutent) combined with docetaxel. A new therapeutic perspective in hormone refractory prostate cancer.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cell Proliferation; Cetuximab; Docetaxel; Gene Expression Profiling; Humans; Indoles; Male; Mice; Mice, Nude; Neoplasms, Hormone-Dependent; Prostate-Specific Antigen; Prostatic Neoplasms; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sunitinib; Survival Rate; Taxoids; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2008 |
Sunitinib (sutent)-induced thyrotoxicosis due to destructive thyroiditis: a case report.
Topics: Humans; Indoles; Male; Middle Aged; Prostatic Neoplasms; Pyrroles; Sunitinib; Thyroiditis; Thyrotoxicosis | 2007 |
Atorvastatin and celecoxib inhibit prostate PC-3 tumors in immunodeficient mice.
Topics: Animals; Apoptosis; Atorvastatin; Celecoxib; Cell Proliferation; Cyclooxygenase Inhibitors; Drug Therapy, Combination; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Injections, Intraperitoneal; Male; Mice; Mice, SCID; Prostatic Neoplasms; Pyrazoles; Pyrroles; Sulfonamides; Xenograft Model Antitumor Assays | 2007 |
Aspirin and hormone therapy for prostate cancer.
Topics: Androgen Antagonists; Aspirin; Atorvastatin; Drug Therapy, Combination; Flutamide; Gonadotropin-Releasing Hormone; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Liver Function Tests; Logistic Models; Male; Prostatic Neoplasms; Pyrroles | 2007 |
Targeted cytotoxic analogue of somatostatin AN-238 inhibits growth of androgen-independent Dunning R-3327-AT-1 prostate cancer in rats at nontoxic doses.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Screening Assays, Antitumor; Male; Octreotide; Prostatic Neoplasms; Pyrroles; Rats; Receptors, Somatostatin; Tumor Cells, Cultured | 1998 |
Targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207 inhibits the growth of PC-82 human prostate cancer in nude mice.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Doxorubicin; Drug Delivery Systems; Gonadotropin-Releasing Hormone; Humans; Male; Mice; Mice, Nude; Models, Chemical; Polymerase Chain Reaction; Prostatic Neoplasms; Pyrroles; Receptors, LHRH; Transplantation, Heterologous; Tumor Cells, Cultured | 1999 |
Inhibition of PC-3 human androgen-independent prostate cancer and its metastases by cytotoxic somatostatin analogue AN-238.
Topics: Androgens; Animals; Antibiotics, Antineoplastic; Doxorubicin; Gene Expression; Humans; Lymphatic Metastasis; Male; Mice; Mice, Nude; Neoplasm Metastasis; Neoplasm Transplantation; Prostatic Neoplasms; Pyrroles; Receptors, Somatostatin; Somatostatin; Transplantation, Heterologous; Tumor Cells, Cultured | 1999 |
In vivo inhibition of PC-3 human androgen-independent prostate cancer by a targeted cytotoxic bombesin analogue, AN-215.
Topics: Animals; Antibiotics, Antineoplastic; Bombesin; Carboxylic Ester Hydrolases; Doxorubicin; Humans; Male; Mice; Mice, Nude; Prostatic Neoplasms; Pyrroles; Receptors, Bombesin; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2000 |
Effective treatment of experimental DU-145 prostate cancers with targeted cytotoxic somatostatin analog AN-238.
Topics: Animals; Antibiotics, Antineoplastic; Cell Division; Cytotoxins; Doxorubicin; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; Mice, Nude; Neoplasm Transplantation; Neoplasms, Experimental; Octreotide; Prostatic Neoplasms; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Neoplasm; Treatment Outcome; Tumor Cells, Cultured | 2002 |